MedWatch

Ambu eyes return to double-digit growth with fewer launches

A new strategy with fewer but more expensive endoscopes will put the Danish medtech company back on the growth track, it hopes.

Photo: Ambu/PR

Going forward, Ambu must become a far more focused company, one that only targets product launches with high sales value. Its commercial division must also train its sights only on the most profitable markets and customers.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs